Pharma Focus Asia

Tonix Pharmaceuticals Plans New Clinical Scale Manufacturing Facility in US

Introduction:

Tonix Pharmaceuticals Holding Corp, plans to open new manufacturing facility. The new R&D facility will address Advanced Development Center (ADC) for vaccine programs.

Features:

The new Advanced Development Center (ADC) will support research, development and analytical capabilities which also includes the production of quality trial vaccines for infectious diseases such as COVID-19.

The Advanced Development Center (ADC),comprises of single-use bioreactors and purification suites. Moreover when the facility becomes fully operational, Good Manufacturing Practice (GMP) production of vaccines for clinical trialswill have the capacity to produce sterile vaccines in glass bottles.

The facility is expected to hire 70 employees including scientists, researchers, manufacturing and technical support staff.

The construction of the site has begun and expected to be fully operational in first half of 2022.

Specifications:

NameTonix Pharmaceuticals
TypeNew Construction
Year2022
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference